⚠ Evidence warning: Clinical trials or other evidence do not support the claims that Maca raises brain BDNF in rodents and protects against Parkinson-type nerve damage in rodent models, or that it helps stress, burnout or non-menopausal anxiety. This page keeps it as a report of what people, websites or other media say.

Maca for Mood and Cognitive Function

Mood and Cognitive Function — scientific infographic poster

The Maca-and-mood evidence base is anchored by the Brooks et al. 2008 trial in Menopause, in which 14 postmenopausal women took 3.5 g/day Maca and placebo for 6 weeks each, in either order, and showed significant reductions in the psychological-symptom scores of the Greene Climacteric Scale, including its anxiety and depression subscales, and in measures of sexual dysfunction — with the title of the paper explicitly noting that the psychological improvements were "not related to estrogen or androgen content." Subsequent trials have extended this finding to perimenopausal cohorts and to non-menopausal anxiety contexts. The mechanism is hypothesized to involve brain-derived neurotrophic factor (BDNF) upregulation, serotonergic system modulation, and possibly endocannabinoid signaling through the macamide-FAAH pathway shared with the libido benefit. Memory data come almost entirely from rodent models — Rubio et al. 2007 showed that black Maca reversed scopolamine-induced memory impairment in mice, and several other rodent learning-and-memory studies have shown protective effects against various cognitive insults. Human cognitive trials are sparse and have not consistently shown discrete memory or executive-function improvements. The critical context for the mood evidence is the comparison to selective serotonin reuptake inhibitors (SSRIs): the Maca trials studied women with menopausal symptoms, adults in Peru, and people whose depression was already in remission on an antidepressant, so no trial has tested Maca as a replacement for antidepressant drugs in established moderate-to-severe depression, or as the only treatment for major depressive disorder. This page works through the human trial evidence, the brain-derived neurotrophic factor and serotonin hypotheses, the rodent memory data, and how the Maca evidence compares with selective serotonin reuptake inhibitors and other mood interventions.


Table of Contents

  1. The Brooks 2008 Menopause Trial — Anxiety and Depression Endpoints
  2. The Stojanovska 2015 Climacteric Trial
  3. Brain-Derived Neurotrophic Factor and Neurotrophic Mechanism Hypothesis
  4. Serotonin System Modulation Hypothesis
  5. Endocannabinoid Overlap with the Libido Mechanism
  6. The Rubio 2007 Scopolamine-Reversal Mouse Study
  7. Additional Rodent Memory and Learning Data
  8. Human Cognitive Trials — What We Have and Don't
  9. Maca and Selective Serotonin Reuptake Inhibitors — What the Trials Tested
  10. Mood Uses Studied and Not Studied
  11. Cautions
  12. Key Research Papers
  13. Connections
  14. Featured Videos

The Brooks 2008 Menopause Trial — Anxiety and Depression Endpoints

The single most-cited trial for Maca's mood effects is Nicole A. Brooks et al., "Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content," published in Menopause volume 15 in 2008. The trial was conducted at Victoria University in Australia under blind methodology.

Design: double-blind randomized placebo-controlled crossover trial. 14 postmenopausal women (mean age 56) completed the trial, taking 3.5 g/day Maca powder for 6 weeks and matching placebo for 6 weeks, in either order, over a total of 12 weeks. Symptoms were measured with the Greene Climacteric Scale. Blood levels of estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH) and sex hormone-binding globulin (SHBG) were measured at baseline, week 6 and week 12, and Maca extracts were tested in a yeast-based laboratory assay for estrogen-like and androgen-like activity.

Results for the mood endpoints:

The trial is small (n=14) but the crossover design provides each subject as her own control, which substantially increases statistical power per subject. The effect sizes were large enough to reach statistical significance despite the small sample, suggesting that the underlying psychological-symptom signal is robust at least in the postmenopausal subgroup studied.

Critically, the Brooks 2008 trial was independently conducted (no commercial sponsorship from Maca producers), used a generic Maca powder rather than a proprietary standardized extract, and used a validated menopause symptom scale (the Greene Climacteric Scale) — all of which strengthen the credibility of the finding relative to the manufacturer-sponsored Meissner trial series in the same era.

For the broader menopausal context including the vasomotor and sleep endpoints from the same study, see the Hormonal Balance and Menopause deep-dive.

Back to Table of Contents

The Stojanovska 2015 Climacteric Trial

Lily Stojanovska and colleagues at Victoria University published a follow-up trial in Climacteric volume 18 in 2015: "Maca reduces blood pressure and depression, in a pilot study in postmenopausal women." Design was a randomized, double-blind, placebo-controlled crossover trial in 29 postmenopausal Hong Kong Chinese women, who took 3.3 g/day Maca or placebo for 6 weeks each, in either order, over 12 weeks.

Measurements included estradiol, follicle-stimulating hormone, sex hormone-binding globulin, thyroid-stimulating hormone, blood fats, glucose, serum cytokines and blood pressure; symptoms and quality of life were assessed with the Greene Climacteric Scale, the SF-36, the Women's Health Questionnaire and the Utian Quality of Life Scale. Results:

The Stojanovska trial extends the Brooks finding to a different ethnic population (Chinese rather than Australian) and confirms the depression-sub-score signal in an independent cohort. The additional blood pressure observation is interesting and consistent with some cardiovascular benefit, though it has not been the primary focus of most subsequent Maca research.

The combined Brooks 2008 + Stojanovska 2015 evidence is reasonably persuasive that Maca produces measurable mood improvement in postmenopausal women at 3–3.5 g/day, mediated through some mechanism that does not involve sex hormone elevation. The generalization to other clinical populations (premenopausal women, men, and patients with primary depression unrelated to menopausal transition) is less well-supported.

Back to Table of Contents

Brain-Derived Neurotrophic Factor and Neurotrophic Mechanism Hypothesis

Brain-derived neurotrophic factor (BDNF) is a small protein that supports neuronal survival, synaptic plasticity, and the growth of new neural connections. Reduced brain-derived neurotrophic factor is implicated in the pathophysiology of major depression, and one of the converging mechanisms of action of selective serotonin reuptake inhibitors, exercise, electroconvulsive therapy, and several other antidepressant interventions is the upregulation of brain-derived neurotrophic factor expression in the hippocampus and prefrontal cortex. Brain-derived neurotrophic factor elevation is now considered one of the most reliable molecular signatures of effective antidepressant action.

Preclinical evidence suggests that Maca extracts upregulate brain-derived neurotrophic factor expression in rodent brain tissue. Rodent studies are reported to show brain-derived neurotrophic factor upregulation in response to chronic Maca supplementation, often coupled with measured improvements in hippocampus-dependent learning tasks.

The hypothesized mechanism for brain-derived neurotrophic factor upregulation by Maca is not yet established at the molecular level. Candidate pathways include:

  1. Direct CREB / TrkB pathway activation by Maca-derived compounds — the same upstream pathway activated by selective serotonin reuptake inhibitors and exercise. Some macamides have been shown in vitro to interact with elements of this pathway, though the relevance to in vivo brain concentrations is uncertain.
  2. Indirect activation via reduced cortisol exposure — chronic cortisol elevation suppresses brain-derived neurotrophic factor expression, and any intervention that normalizes hypothalamic-pituitary-adrenal (HPA) axis hyperactivity could secondarily restore brain-derived neurotrophic factor. Maca's modest cortisol-normalizing effects in hypothalamic-pituitary-adrenal-dysregulated subjects (documented in the Meissner trials) would predict this kind of downstream brain-derived neurotrophic factor restoration.
  3. Antioxidant and anti-inflammatory effects — chronic oxidative stress and neuroinflammation both suppress brain-derived neurotrophic factor expression. Maca's antioxidant capacity (discussed on the Energy and Endurance deep-dive) and possible mild anti-inflammatory effects could contribute indirectly.
  4. Nutritional repletion — B vitamins, zinc, and magnesium are all required cofactors in brain-derived neurotrophic factor synthesis or signaling, and modest nutritional contributions from Maca may matter in patients with marginal status.

The brain-derived neurotrophic factor hypothesis is plausible and consistent with the rodent neuropharmacology data, but it has not been directly tested in humans on Maca. A trial measuring serum or cerebrospinal fluid brain-derived neurotrophic factor before and after 12 weeks of Maca supplementation would be informative; to our knowledge, no such trial has been published.

Back to Table of Contents

Serotonin System Modulation Hypothesis

A parallel hypothesis is that Maca modulates the serotonergic system, with mood-relevant downstream effects. The evidence here is mixed and largely preclinical:

The honest framing is that the serotonin system is plausibly involved in Maca's mood effects but is not the dominant mechanism. The lack of direct receptor binding rules out the simplest serotonergic mechanism (selective serotonin reuptake inhibitor-like reuptake inhibition or direct receptor agonism). More likely, any serotonergic effect is indirect, downstream of hypothalamic-pituitary-adrenal axis modulation, brain-derived neurotrophic factor upregulation, or endocannabinoid signaling changes.

Back to Table of Contents

Endocannabinoid Overlap with the Libido Mechanism

One of the most parsimonious mechanistic frameworks for Maca's diverse clinical effects is that a single upstream mechanism — modulation of endocannabinoid tone through macamide-FAAH inhibition — produces effects on libido, mood, anxiety, sleep, and hypothalamic-pituitary-adrenal axis function through the broad role of endocannabinoid signaling in all of these systems.

The hypothesized mechanism is the same as discussed in detail on the Libido and Sexual Function deep-dive: macamides (the N-benzyl fatty acid amides unique to Maca) inhibit fatty acid amide hydrolase (FAAH), the enzyme that degrades anandamide. The result is chronically elevated anandamide tone, which has downstream effects through CB1 receptors expressed densely in:

A single upstream mechanism producing effects across all these systems would explain why Maca produces such a diverse range of clinical effects without easily mapping to a single conventional drug class. The hypothesis is plausible and consistent with the available data but remains to be directly validated in human trials — specifically, measurement of serum or cerebrospinal anandamide before and after chronic Maca supplementation would be the key first-order test.

Back to Table of Contents

The Rubio 2007 Scopolamine-Reversal Mouse Study

The most-cited Maca cognitive-function paper is Julio Rubio et al., "Aqueous and hydroalcoholic extracts of black maca (Lepidium meyenii) improve scopolamine-induced memory impairment in mice," published in Food and Chemical Toxicology volume 45 in 2007. The design used a standard preclinical memory paradigm: male mice received two doses each of an aqueous (0.50 and 2.00 g/kg) and a hydroalcoholic (0.25 and 1.00 g/kg) black Maca extract for 35 days, scopolamine (a muscarinic acetylcholine receptor antagonist) was given to induce a memory impairment, and memory was tested with the Morris water maze (a spatial memory task) and the step-down avoidance test (an associative memory task).

Findings:

The Rubio 2007 study has been the foundation for subsequent claims of Maca as a cognitive or nootropic supplement. The honest interpretation is that the rodent data support a real cognitive-protective effect against a specific acute cholinergic insult (scopolamine), and the modest AChE inhibition mechanism is biologically plausible. The translation to human cognitive enhancement in healthy adults, or to cognitive protection in human Alzheimer's disease, has not been established by human trials — though the Rubio findings have motivated the design of several Alzheimer-model rodent studies that have generally found beneficial effects of Maca on amyloid pathology and behavioral measures of cognition.

Back to Table of Contents

Additional Rodent Memory and Learning Data

Beyond Rubio 2007, several other animal and laboratory studies have examined Maca for cognitive endpoints:

What is not known: the Pino-Figueroa rat result shows that in animals the dose matters — an amount that limited stroke damage at one dose increased it at higher doses — and no human study has worked out which amounts of Maca, if any, protect the brain.

The aggregate preclinical neuroprotection picture is promising but does not yet translate to a clinical recommendation for Maca in Alzheimer's disease, Parkinson's disease, or cognitive decline in humans. Human trials with cognitive endpoints have generally been short and underpowered, and no large randomized trial of Maca for any neurodegenerative condition has been published. In short, Maca has biologically plausible neuroprotective mechanisms supported by rodent evidence, but the human translation remains aspirational rather than evidence-based at this time.

Back to Table of Contents

Human Cognitive Trials — What We Have and Don't

The human cognitive-function evidence for Maca is sparse. The relevant data points:

The absence of large well-designed human cognitive trials means that anyone promoting Maca as a nootropic or cognitive enhancer is extrapolating from rodent data. This extrapolation may turn out to be correct, but for now the evidence supports interest rather than firm conclusions. For memory and thinking, the human evidence on Maca is limited and the rodent data are promising. Human Maca trials have used 1.5–3.5 g a day for 6–12 weeks. The measures with their own research base for thinking skills (regular aerobic exercise, sleep, a Mediterranean-style diet, social engagement, novel learning) are separate from Maca.

Back to Table of Contents

Maca and Selective Serotonin Reuptake Inhibitors — What the Trials Tested

The single most important context for the Maca-mood evidence is how it compares with selective serotonin reuptake inhibitors and other antidepressant drugs. No trial has tested Maca as a replacement for antidepressant drugs in people with established moderate-to-severe depression; the human Maca trials studied women with menopausal symptoms, adults in Peru, and people whose depression was already in remission on an antidepressant.

The comparison:

A 12-week placebo-controlled trial (Dording 2015) gave Maca 3.0 g a day or placebo to 45 women whose depression had remitted on a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor (SNRI) but who had sexual side effects; 42 were analysed. More women reached sexual-function remission on Maca than on placebo (for example, 30.0% vs 20.0% reaching an MGH-SFQ score of 12 or less), the higher remission rates were linked to being postmenopausal, and Maca was well tolerated. A 2025 systematic review and meta-analysis of 11 randomized trials with 859 women covered drug and herbal treatments for antidepressant-induced sexual dysfunction, maca root among them; only two studies could be pooled, bupropion SR 150 mg twice daily improved desire, arousal and orgasm compared with placebo, and the quality of the evidence was rated low.

What the trials tested, by situation:

  1. Mild depressive symptoms around menopause: the Brooks and Stojanovska trials tested 3.3–3.5 g/day for 6 weeks in postmenopausal women; behavioral measures (exercise, sleep, cognitive-behavioral support) have their own research base
  2. Moderate-to-severe depression: none of the Maca trials described here studied people with active moderate-to-severe depression, either with Maca alone or with Maca added to a selective serotonin reuptake inhibitor, a serotonin-norepinephrine reuptake inhibitor or another antidepressant
  3. Selective serotonin reuptake inhibitor-induced sexual dysfunction: the Dording trials added Maca 1.5–3.0 g/day to the existing antidepressant rather than switching antidepressants; the 3.0 g dose improved sexual-function scores in the 2008 pilot, and the 2015 placebo-controlled trial found higher remission rates, mainly in postmenopausal women
  4. Severe or treatment-refractory depression: no Maca trial has studied this group; severe depression, suicidal thoughts or psychotic features are signs that hospitals and mental-health services treat as urgent

Stopping an antidepressant such as sertraline and taking Maca instead has not been studied. Adding Maca to sertraline or another selective serotonin reuptake inhibitor for low libido is what the Dording trials tested, in people whose depression was in remission.

For more on the mood and depression context, see our Depression page.

Back to Table of Contents

Mood Uses Studied and Not Studied

Putting the trial evidence together, the situations studied or proposed for Maca in mood and cognitive support are:

Uses that no Maca trial has tested or supported:

Back to Table of Contents

Cautions

Back to Table of Contents

Key Research Papers

  1. Brooks NA et al. (2008). Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content. Menopause, 15(6):1157-1162. — PubMed PMID: 18784609
  2. Stojanovska L et al. (2015). Maca reduces blood pressure and depression, in a pilot study in postmenopausal women. Climacteric, 18(1):69-78. — PubMed PMID: 24931003
  3. Rubio J et al. (2007). Aqueous and hydroalcoholic extracts of Black Maca (Lepidium meyenii) improve scopolamine-induced memory impairment in mice. Food and Chemical Toxicology, 45(10):1882-1890. — PubMed PMID: 17543435
  4. Rubio J et al. (2006). Effect of three different cultivars of Lepidium meyenii (Maca) on learning and depression in ovariectomized mice. BMC Complementary and Alternative Medicine, 6:23. — PubMed PMID: 16796734
  5. Guo SS et al. (2016). Preservation of cognitive function by Lepidium meyenii (Maca) is associated with improvement of mitochondrial activity and upregulation of autophagy-related proteins in middle-aged mouse cortex. Evidence-Based Complementary and Alternative Medicine, 2016:4394261. — PubMed PMID: 27648102
  6. Pino-Figueroa A et al. (2010). Neuroprotective effects of Lepidium meyenii (Maca). Annals of the New York Academy of Sciences, 1199:77-85. — PubMed PMID: 20633111
  7. Dording CM et al. (2008). A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience and Therapeutics, 14(3):182-191. — PubMed PMID: 18801111
  8. Dording CM et al. (2015). A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women. Evidence-Based Complementary and Alternative Medicine, 2015:949036. — PubMed PMID: 25954318
  9. Pino-Figueroa A et al. (2011). Mechanism of action of Lepidium meyenii (Maca): An explanation for its neuroprotective activity. American Journal of Neuroprotection and Neuroregeneration, 3:87-92. — doi:10.1166/ajnn.2011.1035
  10. Yang Q et al. (2016). Effects of macamides on endurance capacity and anti-fatigue property in prolonged swimming mice. Pharmaceutical Biology, 54(5):827-834. — PubMed PMID: 26453017
  11. Hajdu Z et al. (2014). Identification of endocannabinoid system-modulating N-alkylamides from Heliopsis helianthoides var. scabra and Lepidium meyenii. Journal of Natural Products, 77(7):1663-1669. — PubMed PMID: 24972328
  12. Gonzales-Arimborgo C et al. (2016). Acceptability, safety, and efficacy of oral administration of extracts of black or red Maca (Lepidium meyenii) in adult human subjects: a randomized, double-blind, placebo-controlled study. Pharmaceuticals (Basel), 9(3):49. — PubMed PMID: 27548190
  13. de Aquino ACQ et al. (2025). Pharmacological treatment of antidepressant-induced sexual dysfunction in women: a systematic review and meta-analysis of randomized clinical trials. Clinics (Sao Paulo), 80:100602. — PubMed PMID: 39985829

PubMed Topic Searches

  1. PubMed: Maca for depression / anxiety / mood
  2. PubMed: Maca and BDNF
  3. PubMed: Maca and memory / cognition
  4. PubMed: Maca neuroprotection in neurodegeneration
  5. PubMed: Maca as SSRI adjunct

Back to Table of Contents

Connections

Back to Table of Contents